Wound treatment device
An improved method and device are provided for treating wounds. The device generally comprises a wound chamber and/or deployment system. The provided assembly substantially improves wound treatment.
1. An ocular and/or periocular wound treatment device, comprising:
a deployment system initially containing a therapeutic agent and including tubing configured to connect the deployment system to an eye shield assembly;
an eye shield assembly, the eye shield assembly including:
a means for attachment to a patient with a temporary adhesive
at least one raised connector extending upwardly from the eye shield assembly configured to connect to the tubing, the raised connector defining an aperture through the eye shield assembly through which the therapeutic agent is configured to be delivered through the eye shield assembly, and
one or more passages to allow gas to escape, the one or more passages being planar openings through the eye shield assembly at different locations than the aperture through which the therapeutic agent is configured to be delivered through the eye shield; and
wherein the device may continuously remain in place during and after therapeutic agent delivery with the one or more passages allowing gas to escape from the eye shield assembly to prevent buildup of pressure in the eye shield from damaging the patient's eye,
wherein the therapeutic agent comprises a thermoreversible polymer formulation including a poloxamer.
2. The wound treatment device of claim 1 , where the eye shield assembly further comprises at least one luer connector.
3. The wound treatment device of claim 1 , wherein the temporary medical adhesive comprises a hydrogel adhesive.
4. The wound treatment device of claim 1 , wherein the eye shield assembly further comprises a nonstick backing.
5. The wound treatment device of claim 1 , wherein the eye shield assembly further comprises a compliant layer to provide a soft surface and/or allow the device to better contour to the patient's face.
6. The wound treatment device of claim 5 , wherein the compliant layer comprise a foam layer.
7. The wound treatment device of claim 1 , wherein the deployment system further comprises a cap configured to indicate if the deployment system has been previously opened.
8. The wound treatment device of claim 1 , wherein the device is provided sterile.
9. A method of treating an ocular and/or peri-ocular wound, comprising:
removing a nonstick device backing from an eye shield;
positioning the eye shield on a patient with an adhesive;
delivering a therapeutic agent from a canister to the patient through the eye shield via tubing; and
leaving the eye shield in place during and after therapeutic agent delivery, and wherein the eye shield includes one or more passages that allow gas to escape from the eye shield to prevent buildup of pressure in the eye shield from damaging the patient's eye, the one or more passages being different openings than the aperture through which the therapeutic agent is delivered,
wherein the therapeutic agent comprises a thermoreversible polymer formulation including a poloxamer,
wherein the thermoreversible polymer formulation comprises an alginate configured to increase viscosity of the thermoreversible polymer formulation and/or to assist with preventing, slowing and/or stopping bleeding and/or fluid leakage.
10. The method of claim 9 , further comprising disconnecting the tubing after delivering the therapeutic agent to facilitate ambulation, transport, and/or patient comfort.
11. The method of claim 9 , wherein the method includes using at least one luer connector to allow therapeutic agent deployment.
12. The method of claim 9 , wherein the method includes spreading the therapeutic agent topically over tissue.
13. The method of claim 9 , wherein the poloxamer is at least one of P407 and P188.
14. The method of claim 9 , wherein the thermoreversible polymer formulation includes a buffer system.
15. The method of claim 14 , wherein the buffer system produces the thermoreversible polymer formulation with a pH between 6.0 and 8.0.
16. The method of claim 9 , wherein the thermoreversible polymer formulation includes an expanding gas.
17. The method of claim 16 , wherein the expanding gas is at least one of HFC134 and AFA1234Z.
18. The method of claim 9 , wherein the thermoreversible polymer formulation includes a preservative.
19. A method of treating an ocular and/or peri-ocular wound, comprising:
removing a nonstick device backing from an eye shield;
positioning the eye shield on a patient with an adhesive;
delivering a therapeutic agent from a canister to the patient through the eye shield via tubing; and
leaving the eye shield in place during and after therapeutic agent delivery, and wherein the eye shield includes one or more passages that allow gas to escape from the eye shield to prevent buildup of pressure in the eye shield from damaging the patient's eye,
wherein the therapeutic agent comprises a thermoreversible polymer formulation including:
a poloxamer,
an alginate configured to increase viscosity of the thermoreversible polymer formulation and/or to assist with preventing, slowing and/or stopping bleeding and/or fluid leakage,
a buffer system,
an expanding gas, and
a preservative.